Matthew Porteus
Scientific Founder & Advisory Board MemberDr. Matthew Porteus, Ph.D., M.D.,is Director of Arbor Biotechnologies, Inc. from October 2025. He is Co-Founder & Executive Director of Kamau Therapeutics, Inc and serves as its Chief Scientific Officer from September 2025. Dr. Porteus is Scientific Founder & Advisory Board Member of CRISPR Therapeutics, Inc. Dr. Porteus serves as Member of Scientific Advisory Board at Alaunos Therapeutics, Inc. (formerly known as ZIOPHARM Oncology, Inc.) since September 2020. He is Member of Scientific Advisory Board at Dispatch Biotherapeutics, Inc. He is a Member of Scientific Advisory Board at Allogene Therapeutics, Inc. He is a Member of Advisory Board at Synthego Corp. since October 2018. He is an Academic Founder and also served as a Director of Graphite Bio, Inc. since March 2020 until March 21, 2024. He serves as Scientific Founder and Advisory Board Member of CRISPR Therapeutics AG. Dr. Porteus is an Associate Professor of paediatrics (Stem Cell Transplantation), Department of Pediatrics; Divisions of Hematology/Oncology and Human Gene Therapy, at Stanford School of Medicine. Prior to joining Stanford, Dr. Porteus served as an assistant professor at the University of Texas Southwestern Medical Center from February 2003 to August 2010. He has a clinical practice at the Lucille Packard Children’s Hospital, where he is an attending physician for the Pediatric Bone Marrow Transplant Service. For his post-doctoral work, he trained with Dr. David Baltimore at the Massachusetts Institute of Technology (MIT) and the California Institute of Technology. It was during his post-doctoral work that he began genome editing and he was the first to show that engineered nucleases could be used to precisely modify human cells by homologous recombination. He graduated Magna Cum Laude from Harvard University before his MD and PhD degrees at Stanford. His PhD focused on the molecular biology of mammalian forebrain development. He completed his residency training in pediatrics at Boston Children’s Hospital and his fellowship training in Pediatric Hematology/Oncology at Boston Children’s Hospital and the Dana Farber Cancer Institute. For his post-doctoral work, Dr. Porteus trained at the Massachusetts Institute of Technology and the California Institute of Technology.
Positions
- Company NameCRISPR Therapeutics AGStock CodeCRSPPositionScientific Founder & Advisory Board MemberColleagues
- SKSamarth KulkarniCEO & Chairman
- JRJames R. KasingerGeneral Counsel & Secretary
- RYRaju Yashaswi PrasadExecutive Officer
- NPNaimish PatelChief Medical Officer
- SFShaun FoyCo-Founder
- EMEmmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board Member
- CCCraig C. MelloScientific Founder & Advisory Board Member
- MPMatthew PorteusScientific Founder & Advisory Board Member
- DGDaniel G. AndersonScientific Founder & Advisory Board Member
- Company NameAlaunos Therapeutics, Inc.Stock CodeTCRTPositionMember of Scientific Advisory Board
